Opioids Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Immediate-Release Short-Acting Opioids and Extended-Release Long-Acting Opioid), Application (Pain Management, Anaesthesia, Diarrhoea Suppression, Cough Suppression, De-Addiction, and Others), Route Of Administration (Oral, Injectable, and Transdermal Patch), Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South & Central America)
The Opioids market is expected to grow from US$ 12.93 billion in 2023 to US$ 15.03 billion by 2031; it is anticipated to record a CAGR of 1.9% from 2023 to 2031.
Opioids are a broad group of medicines majorly used for relieving pain. These medicines are highly effective but can also leads to an addiction. Opioid acts by working on brain receptors and thus provide the varieties of effect including the pain relief. Opioid includes heroin, morphine, codeine, fentanyl, methadone, tramadol, and other similar substances. The growing opioids market size is attributed to the surging chronic pain incidences across the world. In addition, the increasing geriatric population across the world are fueling opioid market growth. A government initiative focusing on the development of medication to prevent and treat opioid overdose and disorders is likely to bring new opioids market trends during the forecast period.
Strategic Initiatives by Market Players will Create an Opportunity for Opioid market growth.Opioids market players invest in R&D activities to ensure the development of effective products. In May 2023, Indivior PLC received the US Food and Drug Administration (FDA) approval for OPVEE (nalmefene) nasal spray for emergency use to treat suspected or known opioid overdose induced by synthetic or natural opioids in adults and pediatric patients aged 12 years and more, which is characterized by CNS and/or respiratory depression. Further, in December 2021, Sandoz announced the launch of its generic Narcan (naloxone hydrochloride) Nasal Spray 4mg in the US; the product is used to reverse opioid overdose. Individuals in the US can immediately obtain Narcan via retail pharmacies and institutions, including hospitals. Lastly, in August 2023, Emergent BioSolutions launched the over-the-counter NARCAN Nasal Spray, making it possible for everybody to help save a life from an opioid overdose emergency. Therefore, strategic initiatives are likely to offer growth opportunities to the opioids market in the coming years.
Based on geography, the Opioid market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global Opioid market in 2023 owing to the lifestyle factor. However, Asia Pacific is predicted to register the highest CAGR during 2023–2031. The US held the largest share of the Opioid market in North America in 2022. US market players are adopting organic and inorganic strategies for Opioid market development. For instance, in 2024, Hikma Pharmaceuticals PLC launched Fentanyl Citrate Injection, USP, in 25mcg/0.5mL and 50mcg/mL doses. Hikma introduced the first FDA approved 25mcg/0.5mL presentation to the US market. The company is expected to expand its portfolio with the launch, broadening the choice of medicines available to hospitals. Furthermore, in 2023, Rusan Pharma launched its state-of-the-art API facility in Madhya Pradesh, India. The facility is designed to meet stringent international regulatory guidelines, ensuring the highest level of compliance. With the production capability of 400 metric tons of APIs annually. This facility expansion will ensure the security of supply of critical APIs to meet the growing demand for addiction treatment and pain management products in India and globally. Moreover in 2023, Neuraxpharm announced the closing of the acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. The well-established products that Neuraxpharm acquired includes 15 products addressing CNS disorders and two products in pain and vascular diseases, and in 2022, Collegium Pharmaceutical, Inc. announced that it completed the acquisition of BioDelivery Sciences International Inc. BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions. BDSI’s commercial growth driver, BELBUCA, is a meaningfully differentiated schedule III opioid product and is highly complementary to Collegium’s portfolio of pain products. Thus, the factors mentioned above support the market growth.
Reasons to buySave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the opioids market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global opioids market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the opioids market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Please Note: It will take 3-5 business days tocomplete the report upon order confirmation for delivery of the full report andexcel data pack. for on demand reports